Connect with us

Announcements

Therapix Announces Product License for CannAmide, a Non-Opiate Pain Relief

Skylar Abbot

Published

on

Therapix Announces Product License for CannAmide, a Non-Opiate Pain Relief
- Ad -

Therapix Biosciences is developing cannabis-based treatments and recently announced the release of a product license for Palmitoylethanolamide, or PEA, an oral tablet called CannAmide. Health Canada’s Natural and Non-prescription Health Products Directorate recommends it as an anti-inflammatory as well as to relieve chronic pain. The tablet is made of 400mg PEA and is recommended to take 1-3 times a day. Chronic pain affects 38% of people around the world and according to the WHO, half of the conditions responsible for living with a disability involving the presence of pain.

CannAmide now offers a safe and non-opiate option for pain relief. It works by regulating the endocannabinoid levels by enhancing receptor sensitivity. It is considered safe to use as it has little to no concern of abuse. It does, however, have a low solubility in terms of an analgesic. CannAmide is unique as it offers an immediate release to improve bioavailability. Therapix guarantees the quality and consistency of the product and is a huge win for the company. It is also a result of the partnership between Therapix and Destiny. Destiny Bioscience offers the entourage effect of botanical and endogenous cannabinoids.

The companies are thrilled with the approved product license and it bodes well for the future of their partnership. Most importantly, it demonstrates the progressive movement towards natural and non-pharmaceutical forms of pain treatment and management.

Skylar is a very valuable writer at COR with over a decade of decorated writing history as well as a Master’s Degree in Business. She considers herself an artist when it comes to authoring diverse guides and coherent reviews on many different topics of interest, especially the cannabis and CBD industries.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com